Clinical Trials
26 trialsNCT01950572 2026-06-05
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Recruiting
NCT06760819 2026-06-04
panSOHO
Bayer
Phase 2 Recruiting
NCT07197554 2026-06-02
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
SEED Therapeutics, Inc.
Phase 1 Recruiting
NCT03801083 2026-06-01
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
University of Pittsburgh
Phase 2 Active not recruiting
NCT07619235 2026-06-01
A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer
Huazhong University of Science and Technology
Phase 4 Not yet recruiting
NCT04956640 2026-05-29
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT06465563 2026-05-29
SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2 Active not recruiting
NCT07614061 2026-05-29
Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer
Shanghai Zhongshan Hospital
Phase 1 Recruiting
NCT05094336 2026-05-28
MTAPESTRY 101
Amgen
Phase 1/2 Active not recruiting
NCT07610798 2026-05-28
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07608458 2026-05-27
Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy
City of Hope Medical Center
Phase NA Not yet recruiting
NCT03875235 2026-05-26
TOPAZ-1
AstraZeneca
Phase 3 Active not recruiting
NCT06188702 2026-05-26
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Servier
Phase 1/2 Active not recruiting
NCT06937567 2026-05-26
CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT07606599 2026-05-26
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07582315 2026-05-22
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06921928 2026-05-20
Study for AZD4360 in Participants With Advanced Solid Tumours
AstraZeneca
Phase 1/2 Recruiting
NCT07334119 2026-05-20
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
Phase 1 Recruiting
NCT07599995 2026-05-20
GENE
Sir Run Run Shaw Hospital
Phase 2 Not yet recruiting
NCT05615818 2026-05-19
SAFIR-ABC10
UNICANCER
Phase 3 Recruiting
NCT06529718 2026-05-19
SEVILLA
UNICANCER
Phase 2 Recruiting
NCT07594964 2026-05-19
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
Shenzhen Xinhe Biomedical
Phase 1 Recruiting
NCT04776837 2026-05-15
Predicting Disease Progression and/or Recurrence in Cancer
Massachusetts General Hospital
Completed
NCT05512377 2026-05-14
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
Boehringer Ingelheim
Phase 2 Terminated
NCT06467357 2026-05-14
DESTINY-BTC01
AstraZeneca
Phase 3 Recruiting
NCT07265674 2026-05-14
Beacon-BTC
J-Pharma Co., Ltd.
Phase 3 Recruiting